Inogen Inc (NASDAQ:INGN) Director Raymond Huggenberger sold 10,500 shares of the firm’s stock in a transaction on Friday, September 14th. The shares were sold at an average price of $282.57, for a total value of $2,966,985.00. Following the completion of the sale, the director now owns 8,797 shares of the company’s stock, valued at $2,485,768.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Raymond Huggenberger also recently made the following trade(s):

  • On Wednesday, August 15th, Raymond Huggenberger sold 10,500 shares of Inogen stock. The shares were sold at an average price of $228.63, for a total value of $2,400,615.00.
  • On Monday, July 16th, Raymond Huggenberger sold 10,593 shares of Inogen stock. The shares were sold at an average price of $194.51, for a total value of $2,060,444.43.

Shares of NASDAQ:INGN opened at $263.88 on Wednesday. Inogen Inc has a twelve month low of $91.80 and a twelve month high of $287.79. The firm has a market capitalization of $6.04 billion, a PE ratio of 201.44, a price-to-earnings-growth ratio of 5.59 and a beta of 1.22.

Inogen (NASDAQ:INGN) last announced its earnings results on Tuesday, August 7th. The medical technology company reported $0.65 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.44 by $0.21. Inogen had a return on equity of 16.51% and a net margin of 10.39%. The company had revenue of $97.24 million during the quarter, compared to analyst estimates of $81.61 million. sell-side analysts predict that Inogen Inc will post 2.07 EPS for the current year.

INGN has been the subject of a number of research reports. BidaskClub upgraded Inogen from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 7th. Zacks Investment Research lowered Inogen from a “buy” rating to a “hold” rating in a research note on Wednesday, September 5th. Piper Jaffray Companies raised their target price on Inogen to $235.00 and gave the company an “overweight” rating in a research note on Monday, July 9th. Stifel Nicolaus set a $258.00 target price on Inogen and gave the company a “buy” rating in a research note on Tuesday, August 21st. Finally, Needham & Company LLC raised their target price on Inogen from $215.00 to $254.00 and gave the company a “strong-buy” rating in a research note on Wednesday, August 8th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $245.00.

A number of hedge funds have recently made changes to their positions in the stock. Zacks Investment Management increased its position in Inogen by 1.6% in the second quarter. Zacks Investment Management now owns 17,033 shares of the medical technology company’s stock worth $3,174,000 after purchasing an additional 261 shares during the period. Fuller & Thaler Asset Management Inc. increased its position in Inogen by 0.4% in the second quarter. Fuller & Thaler Asset Management Inc. now owns 72,381 shares of the medical technology company’s stock worth $13,487,000 after purchasing an additional 291 shares during the period. Sei Investments Co. increased its position in Inogen by 10.5% in the first quarter. Sei Investments Co. now owns 3,073 shares of the medical technology company’s stock worth $377,000 after purchasing an additional 293 shares during the period. Xact Kapitalforvaltning AB increased its position in Inogen by 12.2% in the second quarter. Xact Kapitalforvaltning AB now owns 2,765 shares of the medical technology company’s stock worth $515,000 after purchasing an additional 300 shares during the period. Finally, Mason Street Advisors LLC increased its position in Inogen by 7.8% in the first quarter. Mason Street Advisors LLC now owns 4,799 shares of the medical technology company’s stock worth $590,000 after purchasing an additional 348 shares during the period. Hedge funds and other institutional investors own 96.47% of the company’s stock.

Inogen Company Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

See Also: How to Invest in Marijuana Stocks

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.